Hoechst-Roussel Pharmaceuticals
Executive Summary
Announces June 22 that it will limit its annualized price increases for prescription drugs "to the cumulative forecasted rate of inflation as measured by the Consumer Price Index. The rate will be calculated and weighted over the entire Hoechst- Roussel product line".